Compare PMAX & LYRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PMAX | LYRA |
|---|---|---|
| Founded | 2019 | 2005 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | | Medical/Dental Instruments |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.4M | 5.6M |
| IPO Year | N/A | 2020 |
| Metric | PMAX | LYRA |
|---|---|---|
| Price | $2.04 | $1.19 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $16.00 |
| AVG Volume (30 Days) | 15.0K | ★ 68.9K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,534,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.23 | $0.08 |
| 52 Week High | $5.20 | $37.50 |
| Indicator | PMAX | LYRA |
|---|---|---|
| Relative Strength Index (RSI) | 36.26 | 34.86 |
| Support Level | $1.61 | $1.21 |
| Resistance Level | $2.67 | $1.52 |
| Average True Range (ATR) | 0.16 | 0.18 |
| MACD | -0.05 | 0.03 |
| Stochastic Oscillator | 0.15 | 51.12 |
Powell Max Ltd is an financial communications services provider. Its financial communications services cover a full range of financial printing, corporate reporting, communications and language support services from inception to completion, including typesetting, proofreading, translation, design, printing, electronic reporting, newspaper placement and distribution. It operates in a single business segment which is the provision of corporate financial communications and financial printing services. All operations are carried in Hong Kong.
Lyra Therapeutics Inc is a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients. The Company's operations and manages its business as a single operating segment which is the business of developing targeted medicines to address ears, nose, and throat, or ENT diseases. Its initial product candidates, LYR-210 and LYR-220, are bioabsorbable polymeric matrices designed to be administered in a brief, non-invasive, in-office procedure and intended to deliver continuous drug therapy to the sinonasal passages for the treatment of chronic rhinosinusitis, or CRS.